MicroRNAs (miRNAs) are important for cardiac function and tissue metabolism. The aim of the present study is to investigate the role(s) of miRNAs in the insulin-resistant heart.
Introduction
Type 2 diabetes mellitus (T2DM) is a metabolic disorder characterized by insulin resistance at the whole body and myocardial level. 1, 2 Patients with T2DM are at increased risk of developing cardiovascular disease and have a significantly increased risk of left ventricular dysfunction 3, 4 (LVD), which is independently associated with myocardial insulin resistance. Although the molecular factors contributing to insulin resistance in skeletal muscle have been largely defined, the pathophysiology of myocardial insulin resistance remains poorly characterized. However, down-regulation of Glut4 at the plasma membrane may be particularly important. 5, 6 MicroRNAs (miRNAs) are endogenous, non-coding RNAs that regulate gene expression primarily at the translational level. Recent studies have shown that miRNAs are important for heart development and cardiac hypertrophy 7 -9 and studies of other systems showed a major role for miRNAs in the glucose homeostasis and the pathophysiology of metabolic disease. 10 Among these, the miR-29 family was found to be upregulated in muscle, fat, and liver of Goto -Kakizaki rats, a non-obese model of T2DM and overexpression of miR-29 in 3T3-L1 adipocytes inhibited insulin-stimulated glucose uptake. 11 A separate study in rabbit showed that miR-133 is differentially expressed in diabetic hearts. 12 Together, these findings in the heart and studies in other tissues suggest a role for miRNA in insulin resistance and T2DM. To examine the role(s) of miRNA in insulin signalling and glucose metabolism in the heart, we quantified the expression of 155 miRNAs in left ventricle (LV) biopsies from control patients and patients with T2DM or LVD and determined the effects of miR-223 on cardiomyocyte glucose metabolism.
Methods
Detailed materials and methods applied in this study can be found in the Supplementary methods.
Study population
Consecutive patients awaiting routine cardiac surgery who were suitable for inclusion were invited to take part in the study (Supplementary material online, Table S1 ). The study protocol was approved by the local Ethics Committee and the Administration of Radioactive Substances Advisory Committee in compliance with guidelines. Written consent was obtained from all patients. The investigation conforms with the principles outlined in the Declaration of Helsinki.
RNA isolation
Total RNA was extracted using TriZol reagent (Invitrogen, Paisley, UK) and purified further using mirVana TM miRNA Isolation kit (Ambion/ Applied Biosystems, Warrington, UK), where total small RNA (sRNA) species and large RNAs were isolated as separate samples.
TaqMan qRT-PCR for miRNAs with stem-loop RT primers
Specific mature miRNA species expression levels were quantified by qRT-PCR-based TaqMan miRNA assays (TaqMan MiRNA Assays Human Panel Early Access, Applied Biosystems) using stem-loop primers for reverse transcription (RT) followed by real-time PCR. 13 
miRNA qRT-PCR data analysis
qRT-PCR results were analysed with 7500 Fast System Software version 1.3.0 (Applied Biosystems). Expression fold changes were determined by the DCt method. Further details on the analysis of qRT-PCR data are described in detail in Supplementary methods.
Two-step SYBR Green based qRT-PCR for mRNA
cDNA were synthesized from DNase I (Invitrogen) treated total RNA samples using iScript TM cDNA Synthesis Kit (Bio-Rad). SYBR w Green based q-PCR, was performed using SYBR w Green JumpStart Taq Ready Mix (Sigma).
Histology and in situ hybridization for miRNAs
In situ hybridization was performed as previously described.
14 miRNAs
were detected using miRNA-specific, digoxygenin (DIG) labelled locked nucleic acid probe, or scrambled probe (Exiqon, Denmark). Bound probes were visualized with alkaline phosphotase (AP) labelled anti-DIG fAb fragments (Roche Diagnostics). For routine histological analysis, frozen tissue sections were fixed in 95% ethanol (Fisher Scientific, Loughborough, UK) and stained with haematoxylin and eosin.
Cell culture
Neonatal rat ventricular myocyte (NRVM) cultures were dissociated from 1 -2-day-old neonatal Sprague -Dawley rat hearts as previously described. 15 The investigation conforms with the Guide for the Care and
Use of Laboratory Animals published by the US National Institutes of Health (NIH Publication No. 85-23, revised 1996).
Expression constructs and virus infection
Primary miRNA sequences for miR-223 and miR-296 were cloned into VQ Ad5CMV K-NpA plasmid (ViraQuest Inc., North Liberty, IA, USA). Viral particles were generated and titered commercially by ViraQuest Inc. (North Liberty, IA, USA). 16 Control virus expresses an 'empty vector' which does not carry any transgene. For cell infections, 24 h after treatment with maintenance media, cells were infected with virus at indicated concentrations. All viral expression experiments were performed 24 -46 h after infection.
Northern blotting
Total RNA was separated on denaturing acrylamide gel. RNA was transferred to positively charged nylon membrane (BrightStart, Ambion), and miR-223 was detected using 32 P labelled anti-sense DNA probes.
Glucose uptake assay in cardiomyocytes
NRVMs were isolated and infected with adenovirus encoding miR-223 (Ad-miR-223) or control virus (5MOI). Myocytes were serum starved and glucose uptake measured with minor adaptation to the method described by Moyers et al. 17 In brief, cells were treated with insulin (10 27 M) or vehicle control (30 min), incubated (10 min) in glucose free media containing [ 3 H]2-deoxyglucose and then permeablized with 0.1 N NaOH. Incorporated radioactivity was measured by scintillation counting with correction for non-specific glucose uptake and protein levels.
Antibodies, immunoblotting, and phosphotyrosine immunoprecipitation
Immunoblotting was performed as previously described. 18 For immunoprecipitation, total protein lysates were immunoprecipitated with mouse monoclonal (clone 4G10) anti-phosphotryosine antibody (Millipore) pre-bound to protein sepharose A. Immune complexes were resolved by SDS-PAGE and probed with anti-insulin receptor substrate 1 (IRS1) antibody. Antibodies used: anti-GLUT1, anti-GLUT4 (Abcam, rabbit); anti-phosphoAcetyl CoA Carboxylase (Serine 79), anti-total AKT, anti-phospho-AKT (Serine 473), anti-phospho-GSK3b, anti-IRS1, anti-IRB, and anti-Cox IV (Cell Signaling; all rabbit); anti-Cd36 (rat monoclonal antibody, 1955, R&D Systems) anti-GAPDH (Fitzgerald Industries International, mouse).
AMPK activity
AMP kinase (AMPK) activity was measured by phosphorylation of SAMS peptide (His-Met-Arg-Ser-A&-Met-Ser-Gly-Leu-His-Leu-Val-Lys-ArgArg) as previously described. 19 
Inhibition of Glut4 by RNA interference
Glut4-specific ON-TARGETplus SMARTpool siRNA (siGlut4) and ON-TARGETplus non-targeting siRNA (NT-Ctrl) were purchased from Dharmacon (Thermo Fisher, IL, USA). NRVMs were serum starved and transfected with 100 nM of siRNA using Dharmafect 1. Where appropriate, cells were infected with adenovirus vectors 5 h after transfection. Cells were then incubated at 378C, 5% CO 2 for 48 h before harvest or glucose uptake assay.
Glut4 immunofluorescence
NRVMs were plated onto gelatine-coated eight-well chamber slides at a density of 75 000 cells per well. Cells were treated with serum free maintenance media before infection with adenovirus (5MOI) for 46 h, and stimulated with insulin (10 27 M) for 30 min. For staining, cells were fixed with 4%
(w/v) paraformaldehyde and permeabilized with 0.1% (v/v) triton X-100 (Sigma). Glut4 was stained with Glut4-specific antibody at 1 in 500 dilution (Abcam, Cambridge, UK) and visualized with FITC (Fluorescein isothiocyanate) conjugated anti-rabbit antibody (Invitrogen; 1 in 400). Cells were also stained with rhodamine phalloidin and DAPI (VECTASHIELD Mounting Medium with DAPI) and viewed using Leica TCS SP1 DM IRB confocal fluorescent microscope. All images were captured at Â60 magnification.
Subcellular fractionation
Cytosolic and membrane protein fractions were purified from NRVM infected with Ad-miR-223 or control virus for 48 h using Qproteome
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GLUT4 expressing construct and transfection
Full-length Glut4 cDNA was expressed in COS7 cells, then infected with Ad-miR-223 or control virus at 5MOI. Cells were harvested 24 h after infection, and total protein lysate were collected as previously described. 18 
In silico miRNA target prediction
Five web-based miRNA target prediction programs were used for the prediction of miR-223 target genes: TargetScan, 20 PITA, 21 miRanda, 22, 23 miRBase, 24, 25 and PicTar 26 (see Supplementary material online, Table S3 for URLs). Following program-specific instructions, mature hsa-miR-223 sequence was used to screen for human genes for potential miR-223 target sites.
Luciferase assay
3 0 -UTR sequences flanking the predicted miR-223 target sites were cloned into the psiCHECK-2 plasmid (Promega). Luciferase assay was performed in COS7 cells after adenoviral overexpression using Dual-Glo TM Luciferase Assay System (Promega).
mir-223 inhibition in vivo
miRNA inhibitors comprising complementary sequence to miR-223 and cel-miR-67 (negative control) were from Thermo Scientific Dharmacon products (Lafayette, CO, USA). Ten-week-old C57BL/6 male mice received either mmu-miR-223 inhibitor or negative control inhibitor at a dose of 80 mg/kg body weight or a comparable volume of buffer used to solubilise the ASO (Thermo Scientific Dharmacon Products) through tail vein injection. Tissues were harvested 48 h after treatment.
Statistics
Statistical analyses were performed using MS Office Excel and GraphPad Prism. Clustering was performed using Cluster 3.0. 27 Heatmap was generated using TreeView 1.60 (http://rana.lbl.gov/EisenSoftware.htm). Data are represented as means + SEM and statistical significance tested by Student's t-test or ANOVA.
Results

Expression of miRNAs in the human heart
miRNA expression profiles of heart samples from control and T2DM patients were determined by qRT-PCR. Out of 155 miRNAs represented in the qRT-PCR panel, 115 miRNAs were expressed (Supplementary material online, Table S2 ). Equal amplification efficiency independent of expression levels (Supplementary material online, Figure S1 ) enabled relative quantification of miRNA levels in the control group over a range of four orders of magnitude (Supplementary material online, Table S2 ). The most highly expressed miRNAs detected were miR-133a and b, which are highly expressed in skeletal muscle and the heart. 28,29
Differential expression of miRNAs in the insulin resistant human heart
Expression levels of miRNAs were compared between control patients and patients with T2DM ( Figure 1A ). This revealed upregulated miRNAs (e.g. hsa-miR-342, hsa-miR-223) and downregulated miRNAs (e.g. hsa-miR-214, hsa-miR-199a) in T2DM when compared with control. To prioritize robustly expressed miRNAs with large fold changes, a filter was applied (Ct , 35, fold change ,22 or .2, P 0.05). By these refined criteria, 10% of expressed miRNAs were differentially regulated (P 0.05) in T2DM. A subset of six miRNAs identified in the pooled sample analyses were tested in individual samples, four of these (miR-34a, miR-214, miR-223, and miR-302a) were confirmed ( Figure 1B) . We extended our analyses to samples from patients with LVD, a condition characterized by myocardial insulin resistance. 1, 2 This revealed that miR-223 was the only miRNA that was consistently differentially expressed in the insulin resistant human heart.
Expression of miR-223 in the heart
Previous studies have shown miR-223 to be highly expressed in immune cell types. 30 To determine the expression level of miR-223 in the heart, when compared with other organs, we examined miR-223 expression in mouse tissues by qRT-PCR and Northern blot analyses (Supplementary material online, Figure S2A and B). Both methods showed miR-223 to be most highly expressed in the spleen and lung, moderately expressed in the heart and skeletal muscle, and expressed at low levels in pancreas and brain. To localize miR-223 to a specific cell type in the heart, cryosections were analysed by in situ hybridization (Supplementary material online, Figure  S2C -G). This localized miR-223 expression to cardiomyocytes, with prominent peri-nuclear staining, and also in non-myocytes.
Expression of miR-223 increases basal glucose uptake in cardiomyocytes
Based on our observations in the insulin resistant human heart, 5 we
hypothesized that miR-223 may play a role in cardiac glucose metabolism and/or insulin signalling. We generated adenoviral expression vectors for miR-223 (Ad-miR-223) and miR-296 (Ad-miR-296), a control miRNA unchanged in the diabetic heart. Cultured NRVMs infected with Ad-miR-223 or Ad-miR-296 resulted in the appropriate processing and expression of the mature form of both miRNAs ( Figure 2A and B and Supplementary material online, Figure S3 ). Ad-miR-223 infection significantly increased (1.3-fold, P , 0.05) glucose uptake, in the absence of insulin stimulation, when compared with cells infected with control virus ( Figure 2C ). The increase in glucose uptake in unstimulated Ad-miR-223 infected cells was of a similar magnitude to that observed for control virus infected cells stimulated with insulin (1.3-fold, P , 0.01). No further increase in glucose uptake was detected in cells treated with Ad-miR-223 and insulin. Inhibition of phosphoinositide 3-kinase (PI3K) with wortmannin did not affect the increased glucose uptake induced by miR-223 ( Figure 2D ).
Effects of miR-223 on insulin signalling, AMPK activity, and mitochondrial level
To identify the molecular mechanisms leading to increased glucose uptake in Ad-miR-223 infected cardiomyocytes, we examined the insulin signalling pathway and AMPK activity. At baseline, total levels of Akt, glycogen synthase kinase 3 b-subunit (Gsk3b), insulin receptor b subunit (IRb), and IRS1 were unchanged. Following insulin stimulation, Akt phosphorylation (Ser473) and Gsk3b phosphorylation (Ser9) were significantly attenuated in Ad-miR-223 expressing cells (P , 0.01; Figure 3A) ; IRS1 phosphorylation was unchanged (Supplementary material online, Figure S4 ). In Ad-miR-223 infected cells, MicroRNA-223 regulates cardiomyocyte glucose metabolism there was no change in AMPK activity ( Figure 3B ) or phospho-AcetylCoA carboxylase (ACC) status ( Figure 3C ). These data show that neither canonical insulin signalling nor AMPK activity could directly account for miR-223-induced glucose uptake. In addition to the effects on insulin signalling, perturbation of mitochondrial protein levels has been observed previously in the heart and skeletal muscle in insulin resistant states. 31, 32 To determine whether overexpression of miR-223 effected mitochondrial protein level in NRVM, levels of cytochrome c oxidase (Cox VI) were determined by immunoblotting. No significant variation in Cox VI expression was observed in miR-223 overexpressing NRVM (Supplementary material online, Figure S5 ).
Prioritization of miR-223 targets with a role in glucose metabolism
Five independent miRNA target prediction programs were used to identify potential miR-223 target genes with previously documented roles in glucose metabolism (Supplementary material online, Table S3 ). The predicted target genes identified by more than one algorithm were myotrophin (Mtpn), ras related protein rab-10 (Rab10), nuclear factor IA (NfIa), myocyte enhancer factor 2c (Mef2c), and insulin-like growth factor 1 receptor (Igf1r), which were examined experimentally. Unexpectedly, none of these genes, including three miR-223 targets in immune cells (Mef2c, NFIA, and Igf1r), exhibited a decrease in protein expression following Ad-miR-223 infection of cardiomyocytes. On the contrary, NFIA protein levels were unexpectedly increased in cells overexpressing miR-223 (2-fold, P , 0.01; Figure 4A ). The interaction between miR-223 and predicted mRNA 3 0 -UTR was further examined by luciferase assay in COS7 cells ( Figure 4B) . Consistent with the immunoblot results neither Rab10 nor Mtpn 3 0 -UTRs showed changes in renilla luciferase activity. The 3 0 -UTR of NfIa showed a small, but significant increase in luciferase activity upon miR-223 overexpression (P ¼ 0.012; Figure 4B ).
Glut4 as a miR-223 target
Given that miR-223 neither increased insulin signalling nor altered the protein levels of predicted metabolically active targets, we next examined glucose uptake proteins. miR-223 overexpression increased total cellular Glut4 protein levels (1.3-fold, P , 0.001), whereas Glut1 protein levels were unaltered ( Figure 5A) . No difference in Glut4 mRNA was detected in cells overexpressing miR-223 when compared with control ( Figure 5B ). Given that miR-223 increased the protein levels of NFIA (a known miR-223 target) in NRVMs, the data suggest Glut4 could be a direct target of miR-223. Although in silico sequence analysis of the 3 0 -UTR of Glut4 showed no predicted miR-223 target sites in this region of the transcript, whole cDNA sequence analysis using free energy-based miRNA prediction Table  S4 , S5, and S6). These results suggest Glut4 could be a direct target of miR-223 across species, possible through the interaction of multiple target sites. To test this experimentally, full-length rat Glut4 cDNA was co-expressed with miR-223 in COS7 cells. Levels of miR-223 overexpression (5MOI) in COS7 cells were similar to that observed in NRVM (Supplementary material online, Figure S3 ). Immunoblotting analysis showed a 1.6-fold increase (P , 0.05) in total Glut4 protein by Ad-miR-223 when compared with control virus ( Figure 5C ).
Glut4 upregulation by miR-223 is necessary and sufficient for increased glucose uptake
To test the mechanistic importance of miR-223-induced Glut4 upregulation on glucose uptake, we knocked down Glut4 protein expression using RNA interference ( Figure 5D ). Using this approach, miR-223-induced glucose uptake was completely inhibited. Furthermore, glucose uptake in Ad-miR-223 infected cells treated with siRNA against Glut4 fell below that of control cells ( Figure 5E ).
Cellular localization of Glut4 in miR-223 overexpressing NRVM
The subcellular localization of Glut4 is important in the insulin resistant human heart 5 and for glucose uptake in insulin stimulated cardiomyocytes. 33 We examined the effect of miR-223 on Glut4 subcellular localization using immunoblotting and immunofluorescence ( Figure 6 ). miR-223 increased Glut4 at the plasma membrane in Ad-miR-223 expressing cells ( Figure 5F ). In immunofluorescence experiments, the pattern of Glut4 localization in miR-223 overexpressing cells was similar to that of insulin stimulated cells, with more diffused Glut4 cytoplasmic staining and more pronounced Glut4 staining at plasma membrane ( Figure 6 ). Total Glut4 immunofluorescence was higher in miR-223 infected cells when compared with control cells, in keeping with immunblotting results ( Figure 5A ). MicroRNA-223 regulates cardiomyocyte glucose metabolism
Repression of mir-223 function in vivo using miR-223 inhibitors
Ten-week-old mice were treated with anti-mmu-miR-223, anti-cel-miR-67, or buffer control. miR-223 expression was significantly decreased across all tissues 48 h after treatment with most pronounced inhibition observed in the kidney ( Figure 7A ). In the heart, miR-223 expression was reduced by 50% (P , 0.05) in animals treated with mmu-miR-223 inhibitor when compared with controls.
Total Glut4 levels were assessed in LV samples at the protein and mRNA levels. Immunoblotting revealed Glut4 protein levels to be reduced significantly (33%, P , 0.05) compared with the mice treated with buffer control. The control inhibitor anti-cel-miR-67 had no significant effect on Glut4 expression ( Figure 7B) . No changes in Glut4 mRNA were observed (data not shown). Inhibition of miR-223 had no effect on mitochondrial protein levels in the heart (Supplementary material online, Figure S7 ).
Discussion
In this study, we document the expression levels of 115 miRNAs in the human heart and identify miRNAs that are differentially regulated in the diabetic heart. We then present the first evidence of the involvement of miR-223 glucose uptake in the heart. Our data show that independent of PI3K or AMPK activity, miR-223 increases cellular glucose uptake via Glut4. This increase in glucose uptake was inhibited by using siRNA against Glut4. Thus, miR-223-induced upregulation of Glut4 is necessary and sufficient for the observed increase in glucose uptake. It was notable that following siRNA against Glut4, glucose uptake in miR-223 overexpressing cells fell below that of control cells. This suggests an overall dependence on Glut4-mediated glucose uptake in miR-223 overexpressing cells and may explain why insulin stimulation did not augment glucose uptake in these cells. A consistent effect of miR-223 on Glut4 protein expression was observed in both the gain-of-function experiments in vitro and the loss-of-function experiments in vivo. In vitro, overexpression of miR-223 in cardiomyocytes increased total Glut4 level and induced Glut4 translocation from the cytoplasmic compartment to the cell membrane ( Figures 5 and 6 ). In vivo, inhibition of miR-223 in the heart resulted in a significant decrease in Glut4 expression. It was notable that the effects of synthetic inhibitors on miR-223 inhibition in vivo were pronounced in the kidney and liver, routes of excretion. In diabetic human and mouse hearts, Glut4 is markedly downregulated at the plasma membrane 5 and we suggest that the increased miR-223 levels observed in the diabetic heart are an adaptive/homeostatic response to restore Glut4 expression and normal glucose uptake. This model is in agreement with the idea that miRNAs act as stress response genes and are important for maintaining the robustness of physiological processes in the face of pathophysiological stimuli. 34 -36 In parallel to changes in glucose uptake and Glut4 level, overexpression of miR-223 in vitro inhibited insulin-stimulated Akt and GSK3b phosphorylation in cardiomyocytes. However, there was no change in insulin-stimulated IRS1 phosphorylation and inhibition of miR-223 in vivo did not show improvement in insulin signalling (data not shown). We suggest that the inhibition of insulin-stimulated Akt activity in miR-223 overexpressing cells, which occurs downstream of the insulin receptor/IRS1 complex, reflects feedback inhibition of the insulin signalling pathway due to a sustained increase in glucose uptake in the in vitro overexpression model. Recent studies have shown that miR-223 was increased in the heart in a mouse model of myocardial infarction (MI). 37 It is also known that MI and cardiac ischaemia increase glucose uptake to the heart and insulin-stimulated glucose uptake is beneficial during MI in humans. 38 -40 Hence, it is possible that following MI, miR-223-induced glucose uptake provides a protective mechanism for the heart at a time of severe metabolic stress. 41, 42 Mitochondria stability and protein expression can be affected in insulin resistance states. We examined the levels of MicroRNA-223 regulates cardiomyocyte glucose metabolism mitochondria through both in vitro gain-of-function and in vivo loss-of-function experiments, and found no change in mitochondrial levels in either cardiomyocytes or the LV. This finding suggests that miR-223-induced increase in Glut4 levels and the subsequent increase in glucose uptake are specific effects.
In order to identify the mechanism underlying miR-223-induced glucose uptake, we initially analysed predicted mRNA targets of miR-223 with a known role in glucose metabolism using five independent prediction programs. The genes prioritized using this approach were Rab10, Mtpn, NfIa, Igf1r, and Mef2c. Neither Rab10 nor Mtpn was miR-223 targets in cardiomyocytes, although proteomic analysis in neutrophils cultured from bone marrow of miR-223 2/Y mice revealed increased in Rab10 and Mtpn protein levels. 43 Surprisingly, NfIa, Igf1r, and Mef2c, three previously reported miR-223 targets in immune cells, were not downregulated by miR-223 in cardiomyocytes and protein levels of NfIa were increased by 2-fold following miR-223 overexpression. These findings suggest that miRNA effects are pleiotropic and tissue-specific, and that miRNAs can increase the protein levels of target mRNAs in some cell types, as previously reported in growth-arrested cell lines. 44 MiRNA-induced target gene upregulation may be particularly important in cardiomyocytes that are terminally differentiated. 45 We propose that our observations also provide insights to the importance of miRNAs that are expressed at an intermediate level, which may be particularly effective in regulating mRNA targets. 46 Of note, our current understanding of miRNA-target interactions comes mainly from studies of miRNAs that are highly expressed, such as the study of miR-223 in myeloid cells. 47 While the Glut4 3 0 -UTR is not predicted to contain miR-223 target sites by some programs, its protein levels consistently vary in loss-and gain-of-function studies in vitro and in vivo. This could reflect the limited ability of in silico target identification approaches, as previously described. 47 However, target site prediction analysis using full-length cDNA sequences of Glut4 revealed a number of potential miR-223 target sites in rat, mouse, and man in coding, 5 0 -UTR and 3 0 -UTR sequence, which may interact cooperatively. The occurrence of non-3 0 -UTR miRNA binding sites is a recent and important finding of the ENCODE (Encyclopedia of DNA Elements), which identified multiple miRNA sites throughout coding genes. 48 In conclusion, miR-223 is upregulated in the insulin resistant human heart and when overexpressed enhances PI3K-independent glucose uptake to cardiomyocytes by post-transcriptional upregulation of Glut4. In addition, we show that variation in miRNAs of intermediate expression is important for post-natal tissues homeostasis, as previously suggested. 46 Finally, these data demonstrate the pleiotropy of miRNA function and that miRNA-target genes can be upregulated in terminally differentiated cardiomyocytes.
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